Silexion Therapeutics appoints Avner Lushi to audit committee after Peled resignation

Silexion Therapeutics Corp

Professor Amnon Peled resigned from board and audit committee effective Aug 1, 2026 for personal reasons, no disagreement.
Avner Lushi, existing independent board member, appointed to audit committee effective Aug 1, 2026.
Audit committee now has three independent members: Dror J. Abramov (Chair), Ruth Alon, and Avner Lushi, restoring Nasdaq compliance.
Lushi is Managing Partner and CEO of Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.